Alloimmunization rates reported in various patient populations and disease states*
| Population or disease state . | Reported alloimmunization rate (%) . |
|---|---|
| General adult patients | |
| Retrospective analysis | 1-3 |
| Prospective analysis | 8-10 |
| Hemoglobin disorders | |
| Sickle cell disease | 19-43 |
| Thalassemia major | 5-45 |
| Inflammatory disorders | |
| Autoimmune disorders, general | 16 |
| Inflammatory bowel diseases | 8-9 |
| Lymphoid disorders | |
| Acute lymphoid leukemia | <1 |
| Hodgkin lymphoma | <1 |
| Non-Hodgkin lymphoma | 2-3 |
| Myeloid disorders | |
| Acute myeloid leukemia | 3-16 |
| Myelodysplastic syndromes (includes myelodysplastic/myeloproliferative disorders) | 15-59 |
| Solid tumors, nonhematopoietic | 1-10 |
| Transplantation | |
| Hematopoietic progenitor cell | 1-4 |
| Liver transplant | 4-23 |
| Other sites or multiple organ transplantation | 1-10 |
| Population or disease state . | Reported alloimmunization rate (%) . |
|---|---|
| General adult patients | |
| Retrospective analysis | 1-3 |
| Prospective analysis | 8-10 |
| Hemoglobin disorders | |
| Sickle cell disease | 19-43 |
| Thalassemia major | 5-45 |
| Inflammatory disorders | |
| Autoimmune disorders, general | 16 |
| Inflammatory bowel diseases | 8-9 |
| Lymphoid disorders | |
| Acute lymphoid leukemia | <1 |
| Hodgkin lymphoma | <1 |
| Non-Hodgkin lymphoma | 2-3 |
| Myeloid disorders | |
| Acute myeloid leukemia | 3-16 |
| Myelodysplastic syndromes (includes myelodysplastic/myeloproliferative disorders) | 15-59 |
| Solid tumors, nonhematopoietic | 1-10 |
| Transplantation | |
| Hematopoietic progenitor cell | 1-4 |
| Liver transplant | 4-23 |
| Other sites or multiple organ transplantation | 1-10 |
As reviewed in Hendrickson and Tormey.1